Background and Purpose-High blood pressure (BP) is the most important modifiable stroke risk factor. Worldwide high BP in many people is uncontrolled or people are unaware of their BP status. We aimed to assess whether a program of organized multidisciplinary care and medication would be cost-effective for improving BP control for the prevention of stroke. Methods-A novel aspect was to simulate the intervention to match recent primary care initiatives (eg, new Medicare reimbursement items) to ensure policy relevance. Current practice and additional costs of each intervention were included using the best available evidence. The differences in the cost per quality-adjusted life year (QALY) gained for the interventions were compared against current practice. Cost-effectiveness was defined as cost per QALY gained was less than Australian dollars (AUD) 50 000 (societal perspective; reference year 2004). The robustness of estimates was assessed with probabilistic multivariable uncertainty analysis. Results-For primary prevention, the median cost per QALY gained was AUD11 068 (95% uncertainty interval AUD5201 to AUD18 696) in those aged 75 years or older and was AUD17 359 (95% uncertainty interval AUD10 516 to AUD26 036) in those aged 55 to 84 years with Ն15% absolute risk of stroke. Primary prevention interventions were not cost-effective if aged younger than 50 years. The median cost per QALY gained for secondary prevention was AUD1811 and AUD4704, depending on which medications were modeled. Conclusions-Organized care for BP control targeted at specific populations offers excellent value over current practice.
H ypertension is the most important modifiable risk factor for stroke. In Australia, Ϸ42% of cardiovascular disease and Ϸ7.6% of "all-cause" health loss is attributable to high blood pressure (BP; Ͼ140/90 mm Hg). 1 Although effective treatment for high BP exists, the detection and control of high BP remain worldwide problems. 2 In Australia, BP is uncontrolled in Ϸ8% of people aged older than 25 years and in 60% of treated hypertensive adults. 3 BP may be uncontrolled in treated hypertensive individuals for several reasons, which may include lack of patient compliance with medication or reluctance by physicians to change medications or to prescribe additional medications to achieve BP targets. 4 -6 In survivors of stroke, Ϸ67% at 5 years after a first-ever event receive insufficient treatment to achieve target BP levels. 7 Therefore, improving the control of BP to prevent first-ever and secondary stroke events should be a public health priority. Currently, no formal national primary care programs to improve the control of BP are used in Australia. The main modifiable risk factors for high BP include diet, especially salt intake, inadequate levels of exercise, obesity, and excessive alcohol intake. 8 Realistic changes in diet and lifestyle have been reported to reduce average BP levels by Ϸ2 to 3 mm Hg diastolic. 9 In a recent systematic review, an organized system of regular review and medication (organized care) was found to be the most effective intervention for improving the control of BP. 10 Despite this, there are few data about the value of organized programs that target BP. Moreover, because people often have multiple risk factors, current recommendations are to use an absolute risk approach to cardiovascular disease prevention. 11 It is unclear what the impact of applying such programs, whether focused on single risk factor thresholds or based on an individual's combination of risk factors, might be in Australia.
New policy initiatives to improve primary care prevention management could provide the framework to encourage the implementation of organized BP control programs. These policy initiatives provide additional funding to Australian doctors through Medicare reimbursement items and target 3 main groups: those aged 45 to 49 years as part of the Well Person's Health Check; an annual Older Person's Health Assessment for those aged 75 years or older; and for those with existing diseases, such as stroke and diabetes, Chronic Disease Management planning items are available for promoting more individualized and regular multidisciplinary care. 12 Despite the introduction of these initiatives, there is limited evidence of their effectiveness or cost-effectiveness and there has been inconsistent uptake. Primary care practitioners might be encouraged to use these initiatives and the government might be encouraged to expand the programs if data about the value of such programs were available. We hypothesized that organized care interventions aimed at improving the control and treatment of BP in Australia would be cost-effective compared with current practice management for both the primary and secondary prevention of stroke.
Materials and Methods
Detailed information on the methods and models used in this study is provided in the online-only Supplemental Methods (http://stroke. ahajournals.org). In brief, an established economic microsimulation model was expanded for this project using the updated Model of Resource Utilization Costs and Outcomes of Stroke. 13 The model includes the best available data including stroke incidence and case fatality rates from the North East Melbourne Stroke Incidence Study (NEMESIS) 14 and Australian population statistics by age and gender. The linked spreadsheets enable the reporting of stroke numbers (incident and prevalent cases), lifetime costs, and health outcomes for ischemic stroke and intracerebral hemorrhage. 13 In this present study, new spreadsheets were created to define eligible cases for primary prevention according to each targeted age group (eg, a 45-49 age group was used to conform to eligibility for a Well Person's Health Check). A multidisciplinary reference committee assessed the validity of data inputs and contributed to the interpretation of results, taking into account factors such as equity and feasibility issues, including perceived acceptability to the community.
Costs and benefits were modeled over a lifetime for a 2004 reference year cohort of eligible participants. This reference year was used because it provided the best available data for when the study was undertaken (between 2004 and 2007) . Costs and benefits occurring after the first year were discounted using a 3% discount rate to provide net present values. Supplemental Table I (available online at http://stroke.ahajournals.org) provides a summary of the economic evaluation methods used.
Description of Programs Assessed
To make the analysis meaningful, we designed the interventions to conform to the new general practice policy initiatives outlined. When cases were not eligible for a health assessment, a Medicare item for a long consultation was included for the assessment phase (onlineonly Supplemental Table II) . A further novel feature was to include eligibility criteria using an absolute risk threshold for stroke in a separate analysis. That is, the effects of multiple risk factors were taken into account in considering an individual's likelihood of stroke within a 5-year period. Estimation of absolute stroke risk was undertaken using the stroke risk profile Framingham equation applicable to people aged 55 to 84 years (and includes taking into consideration the presence or absence of diabetes, atrial fibrillation, smoking, preexisting coronary heart disease, and cholesterol and BP levels). 15 Overall, 5 primary prevention pathways were assessed targeting those aged 30 to 69 years (as per the original intervention trial 13 but applied as an effectiveness analysis to Australia), those aged 45 to 49 years; people aged 55 to 84 years with high BP or Ն15% absolute risk of stroke within 5 years, and people aged 75 years or older. Two secondary prevention pathways were also assessed based on achievement of BP goals using different medication regimes (see onlineonly Supplemental Methods).
Online-only Supplemental Table II 13 Cases of transient ischemic attack were also estimated in the ischemic stroke model for this study. The number of incident transient ischemic attack cases was based on a published conservative overall incidence estimate of 0.2%. 16 This estimate was multiplied by the Australian population for 2004 (estimated nϭ40 224).
The proportion of males and females in each target group of interest (eg, those with or without a history of high BP for certain age bands) and the current practice use of prevention medications were obtained from a large audit of Australian general practices (Ͼ16 000 patients; Supplemental Table III available online at http://stroke. ahajournals.org). 17 Two categories of medication use for antihypertensive individuals were established. The current practice mix included the probability of particular medication use regardless of BP level achieved. In contrast, the effective practice mix was the probability of particular medication use when BP was controlled, that is Ͻ140/90 mm Hg in treated hypertensive patients. These probabilities were used to establish the cost of medications for the current practice pathway (current practice mix used) and the intervention pathway (effective practice mix used). People at high absolute risk for stroke were assumed to be prescribed aspirin, a cholesterol-lowering agent ("statins") and BP-lowering medication. The effectiveness of the combinations of these drugs used for the absolute risk of stroke treatment scenario was assumed to be multiplicative based on the relative risk reductions expected from each treatment. 18 
Estimating the Number of Strokes Prevented
Because a meta-analysis for BP control interventions demonstrated significant heterogeneity in the pooled estimates, 10 use of these estimates would not have been appropriate for this analysis. Instead, for primary prevention of stroke, we used the study of greatest size and superior quality from this meta-analysis to base the efficacy estimates. 18 In this randomized controlled trial, the intervention group of people aged 30 to 69 years received lifestyle recommendations, in addition to successive titration of antihypertensive medications and free clinical reviews at least every 4 months for up to 5 years. 19 The reported reductions in stroke incidence were consistent across gender, age, and presence of longstanding high BP. 20 For the secondary (recurrent) stroke prevention effects, we used data from the Perindopril Protection Against Recurrent Stroke (PROGRESS) trial. 21 In this trial, the use of an angiotensinconverting enzyme inhibitor (perindopril) with and without a diuretic (indapamide) was associated with absolute risk reductions over 5 years of 2% for ischemic stroke and 1% for intracerebral hemorrhage. 21 Supplemental Table IV (available online at http://stroke. ahajournals.org) includes a summary of the relative risk reductions for stroke incidence used in this study.
We estimated that 10% of general medical practices in Australia implement the prevention programs. This estimate was based on evidence in the literature for prevention programs that have no additional Medicare incentive payments (eg, practice nurse payments). 22 
Estimation of Costs
We used a societal perspective to estimate costs. This approach incorporated all direct costs to the health sector, as well as productivity costs (ie, loss of ability to work or engage in leisure activities and household production [unpaid work]), out-of-pocket costs to patients, and the costs of informal care-giving associated with stroke events. 13 Additional time costs for attending clinical visits for the primary prevention interventions were estimated for both employed and unemployed people of working age. For each additional clinic visit, the cost of 1 hour of lost time was attributed to the intervention. Time costs were not included for the secondary prevention interventions because lost time associated with stroke is indirectly captured in the quality of life (quality-adjusted life year [QALY]) measurement. 23 Cost of medication was based on the 5 most commonly used classes of antihypertensive medications and the probability of prescribing patterns 17 to capture the cost variation and the use of multiple agents per person. The unit prices for medications were obtained from the Pharmaceutical Benefits Schedule. 24 Medicare schedule fees were used as the best estimate of the unit prices for clinician consultations and diagnostic tests. 25 Supplemental Table V (available online at http://stroke.ahajournals. org) provides a summary of the unit costs for each prevention pathway that was modeled. To cover lag time to effects and management of side effects, different estimates of the costs of treatment were made for the first year and subsequent years of the intervention (Supplemental Tables V and VI, available online at http://stroke.ahajournals.org).
Health Outcomes
Health outcomes were measured as QALYs gained from preventing stroke, with 1 QALY equivalent to 1 year of healthy life. 26 In the present study, we estimated the net difference in the total number of QALYs gained from an intervention over current practice from having prevented first-ever or recurrent strokes. These estimates were calculated for each target group for males and females using quality-of-life data from North East Melbourne Stroke Incidence Study. 26
Analysis
The design of this study is an incremental cost-effectiveness analysis using population level microsimulation. The net differences in costs and health benefits for each pathway of care against the relevant current practice pathway were estimated as the incremental cost per QALY gained 13 (Figure 1) . Interventions in which a cost-saving (negative) result was produced were ranked based on the total health benefits achieved. The interventions that produced more health benefits at an increased cost were considered cost-effective if the cost per QALY gained was less than Australia dollars (AUD) 50 000 per QALY saved. This is a commonly used threshold and is consistent with the decision (or willingness-to-pay) threshold reflected in previous policy decisions for health care programs in Australia. 18 Individual results for males and females and the different stroke types are not presented in this article.
Cost rewards were estimated as the potential cost-offsets obtained from preventing stroke cases attributable to the intervention in 2004. First-ever strokes prevented contributed a lifetime benefit (reward). In contrast, recurrent events only contributed the cost of the first 12 months of treatment. Results without cost-offsets are provided to show the true upfront costs of the interventions because health benefits may not occur in the immediate future.
Sensitivity and Uncertainty Analyses
Univariate (1-way) sensitivity analyses were used to examine the effect of different program options, resulting in larger Medicare payments to increase general practitioner participation. Plausible increases in general practitioner participating were tested from 10% to 26% (for practice nurse payments) and to 70% based on evidence of claims for relevant Medicare practice incentive programs. 27 Because primary prevention interventions for reducing BP also will have an impact on other cardiovascular disease events, such as heart attack, the costs of preventing stroke are potentially overestimated in this study. Therefore, the costs of the program were apportioned more fairly to stroke as part of uncertainty analyses. We refer to this as joint cost attribution. In this present study, the attribution was based on the reported contribution of stroke to the burden of disease 1 with the program costs varied between 40% and 60%.
Multivariable probabilistic uncertainty analyses of nominated epidemiological and cost variables (online-only Supplemental Table  V) were simulated 6000 times using @Risk software version 4.5 (Palisade Corporation). The simulated data were used to estimate a median and 95% uncertainty interval for the outcome measures. Each of the interventions was then ranked in order of costeffectiveness. In addition, the relative risk reduction for 55-to 84-year-olds, which was based on the overall estimate for 30-to 69-year-olds, was substituted for the 60-to 69-year-old age group's relative risk reduction in an uncertainty analysis, because this may have been more appropriate.
Results
The estimated target populations for 2004 were based on an Australian population of 20.1 million. If 10% of general practitioners adopted the organized care interventions outlined, we then estimated that there would be 117 931 patients with a previous stroke or new transient ischemic attack or stroke in 2004 eligible for the program (Table 1 and onlineonly Supplemental Table VII ). The numbers of eligible patients for the primary prevention interventions ranged from 10 000 to Ͼ200 000.
Compared to current practice, interventions of organized management were most cost-effective for those aged 75 years or older (median cost per QALY gained AUD11 764 [95% uncertainty interval, AUD5201 to AUD18 696]), those aged 55 to 84 years with Ն15% risk of stroke over 5 years (56% male; median cost per QALY gained AUD18 201 [95% uncertainty interval AUD10 516 to AUD26 036]), and those who had already had a stroke event (median cost per QALY gained AUD1811 and AUD4704, depending on the medications used; Table 1 ). The most cost-effective interventions were those for secondary prevention, which also prevented the greatest number of strokes and remained cost-effective irrespective of whether cost-offsets from the strokes prevented were included or excluded ( Figure 2 ). In uncertainty analyses, between 33% and 65% of the iterations for secondary prevention interventions were cost-saving.
Basing treatment in the 55-to 84-year age group using a BP threshold alone would capture many more eligible cases than when using the absolute risk approach (ie, 140 038 vs 10 910, respectively), but there was only a 60% probability that the former intervention was cost-effective. However, if a proportion of program costs were attributed to the prevention of other vascular diseases, the intervention aimed at people aged 75 and older would be cost-saving and the program targeting hypertensive 55-to 84-year-olds became costeffective (median AUD18 692; 95% uncertainty interval, AUD7405 to AUD48 970; Table 2 ).
When additional Medicare practice incentive payments (eg, these payments are designed to assist with developing infrastructure, such as employment of practice nurses and use of recall registries to improve the quality of care) 28 were assessed in sensitivity analyses, the additional costs associated with these incentives did not alter the ranking of the interventions, but rather increased the potential impact of the programs in preventing stroke (Supplemental Table VIII , available online at http://stroke.ahajournals.org).
Discussion
The results from this study provide new important evidence of the value of an organized system of regular review and medication to improve the control of BP. Our organized care interventions that were developed to be consistent with ACEi indicates angiotensin-converting enzyme inhibitor; AUD, Australian dollars; BP, blood pressure; QALY, quality-adjusted life year. *Total costs of program assuming no one in the eligible target group is already using treatment. †Net program costϭthe total intervention cost for the target group minus the estimated average current practice costs per eligible person who may have already been receiving treatment for high blood pressure in that population group. This represents the true cost of providing the intervention over and above what is currently spent.
Figure 2.
Cost-effectiveness with and without cost-offsets of secondary prevention. The decision threshold was AUD50 000 per quality-adjusted life year (QALY) gained. For the right quadrants, point estimates for the cost per QALY gained that are above the X-axis are costeffective, whereas those that are below the X-axis are cost-saving. Cost-offsets refer to resources that would be available from the prevention of stroke events. AUD, Australian dollars; Ϫ, decision threshold AUD50 000 per QALY saved; Ⅺ, any medications without cost-offsets; E, best practice medications with costoffsets; OE, any medications with costoffsets; ϫ, best practice medications without cost-offsets.
national primary care initiatives were cost-effective for people aged older than 55 years or who have already experienced a stroke event, regardless of whether additional program elements or practice incentive payments were added. Secondary prevention options provided the largest number of preventable strokes and the greatest potential gain in QALY. This is important because the cumulative risk of recurrent stroke over the course of 10 years is Ϸ43%, and there remains sizable undertreatment of BP in this population. 7, 29 Currently, no formalized programs focused on improving the control of BP has been adopted in Australia. Data from recent large community surveys provide evidence that many Australians would benefit from having greater awareness of the relationship between BP and stroke, and the issue of uncontrolled BP remains large. 30 Furthermore, there is substantial undertreatment of patients based on the absolute risk assessment of multiple risk factors for cardiovascular disease. 31 We demonstrated the societal value of a broad BP control program for stroke prevention that can address multiple risk factor prevention.
The rationale for investing in treatment starting at age 55 years is also supported by evidence that elevated BP in midlife can increase the risk of stroke when older. 32 Therefore, the potential to treat more people and to prevent a greater number of strokes based on considering BP level alone may be justified. However, the absolute risk approach was more favorable in terms of cost-effectiveness in people aged 55 to 84 years. One could argue that the absolute risk methods derived from the Framingham risk prediction equation are not applicable to Australia. However, several investigators have provided evidence that this equation is reliable for use in Australia. [33] [34] [35] A major limitation of the absolute risk approach is that it may underestimate risk in certain populations (eg, Indigenous populations or in those with kidney disease). 33 Therefore, management of risk factors in these circumstances is warranted without full absolute risk assessment. Another relevant point to note was the decision to include aspirin as a primary prevention measure, which subsequently has been found to be of uncertain net value, because the reduction in occlusive events needs to be weighed against any increase in major bleeds. 36 However, removing this element would not have changed the ranking of the interventions. In addition, it was not possible to report on the independent effects of different program elements (such as lifestyle changes and the impact on BP risk factors) using the efficacy summary estimates. Furthermore, changes in population awareness of the causes of stroke and better prevention management and treatment of stroke may be additional factors that influence reductions in mortality. These factors may be sources of overestimation in survival benefits.
Overall, the results of the present study are consistent with those in other published studies on cardiovascular disease prevention. [37] [38] [39] Although, comparisons with the results from the present study are problematic because different assumptions, populations, outcomes, and prevention interventions have been assessed; nonetheless, this literature supports, on face value, that the evidence is consistent.
Conclusions
The aging of the population in many countries means that it is imperative to tackle the prevention of stroke events using strategies that are cost-effective and consistent with current policy initiatives to ensure rapid translation. Few investigators have explored the cost-effectiveness of BP control programs in primary care. This present study is the first to incorporate such an approach for stroke in Australia using economic analysis combined with objective feedback from a broad reference group. A novel aspect was to fit the intervention within current primary care policies to ensure greater relevance. Programs to improve the control of BP in people aged 55 years and older and as secondary prevention were worthwhile and should be established in Australia and elsewhere. 
Additional information on economic modeling methods
New policy initiatives to improve the assessment and follow-up of patients in primary care were used to base the economic modeling simulation framework for the implementation of organized blood pressure control programs in Australia. These policy initiatives provide additional funding to doctors through Medicare reimbursement items and target three main groups:
(1) A Well Person s Health Check for people aged 45 to 49 years with one identifiable risk for a chronic disease. This health check is aimed at identifying risk factors in individuals and promoting lifestyle changes and/or pharmacological treatment. People with one modifiable risk factor are offered individual or group lifestyle counseling and education services.
(2) The Older Person s Health Assessment is an annual health assessment for those aged 75+ years.
(3) Chronic Disease Management (CDM) items are available for those with existing diseases such as stroke and diabetes. These items are aimed at promoting more individualized and regular multidisciplinary care planning in those with underlying disease. In this study, use of such plans was assumed to be organized following an initial assessment visit (such as those outlined in items 1 and 2 above).
For the present economic evaluation the following pathways for different target groups were assessed. Primary prevention pathways: For primary prevention of stroke, we used the study of greatest size and superior quality from the Fahey et al meta-analysis to base the efficacy estimates 2 . In the Hypertension Detection and Follow-up Program (HDFP) trial, about 11,000 participants with a diastolic BP 90 mmHg were followed for five years and the intervention group received lifestyle recommendations, in addition to successive titration of antihypertensive medications and free clinical reviews at least every 4 months. The intervention group had significant reductions in stroke mortality (6.9 per 1,000) and reduced stroke incidence (1.9%, compared with 2.9% in the control group) 3 . The reduction in stroke incidence was consistent across gender, age and presence of longstanding high BP, and was present irrespective of treatment and end-organ damage status at baseline. In our models, we also included a 30 to 69 year age group to conform with age bands used in the HDFP trial 1 .
For the secondary (recurrent) stroke prevention effects, we used data from the Perindopril Protection Against Recurrent Stroke (PROGRESS) trial 4 whereby the use of an angiotensin converting enzyme (ACE) inhibitor (perindopril) with and without a diuretic (indapamide) was assessed in about 6,000 patients with a history of stroke and/or TIA. Active treatment was associated with absolute risk reductions over five years of 2% for ischemic stroke and 1% for ICH 4 . In the present study, the number of incident TIA cases was based on a published conservative overall incidence estimate of 0.2% 5 . This estimate was multiplied by the Australian population for 2004 (estimated n=40,224). Because the actual incidence of TIA in Australia is unknown this rate was varied in uncertainty analyses up to 0.8%. For prevalent and TIA cases, the use of antihypertensive agents was based on the figures derived from the ASAP dataset in cases reported as having had a previous stroke or TIA.
Cost rewards were estimated as the potential cost-offsets obtained from preventing stroke cases attributable to the intervention in 2004. First-ever strokes prevented contributed a lifetime benefit (reward). In contrast, recurrent events only contributed the cost of the first 12 months of treatment where it was assumed that resource utilization would return to the same level as a first-ever stroke after 12 months. The cost-offsets were subtracted from the intervention costs. Results without cost-offsets were also provided to show the true upfront costs of the interventions since health benefits may not occur in the immediate future.
Treatment coverage was set at 10% of general medical practice settings in the base scenario. This figure of 10% is that used by others for prevention programs that have no additional Medicare incentive payments 6 . This assumed coverage figure was altered in sensitivity Since primary prevention interventions for reducing BP will also have an impact on other CVD events, such as heart attack, the costs of preventing stroke are potentially overestimated in this study. Therefore, the costs of the program were apportioned more fairly to stroke as part of uncertainty analyses. We refer to this as joint cost attribution. In this present study, the attribution was based on the reported contribution of stroke to the burden of disease 8 .
Overall, stroke contributes about 25% of disease burden from CVD in Australia. However, if only ischemic heart disease and hypertensive heart disease are considered, the contribution from stroke is about 45% 8 . Therefore, the program costs were varied between 40% and 60% to be conservative.
Explanation for formula used in the models:
Several steps are used to calculate the final cost-effectiveness ratios for each intervention pathway that was evaluated in this study. To make the explanation more meaningful, a worked example is provided for people aged 55 to 84 years with no history of stroke and identified as having high blood pressure. Note each of these steps from Step 2 are estimated separately in the ischemic stroke model and intracerebral hemorrhage model 9 and the results for each model was then summarised in a separate results workbook.
Step 1: Estimate the size of the eligible population who will receive the intervention (see Figure S1 )
Step 2: Calculate the number of expected strokes if a) the eligible population receives current practice by multiplying the NEMESIS incidence rates for the appropriate target group age band and b) the eligible population that receives the intervention. Subtract results of (a) from (b) to give the net difference in stroke events. Example: for estimating the number of ischemic stroke events in those aged 55 to 84 years without a history of prior stroke: Part (a) Males: 65,567 x ischemic stroke incidence rate if aged 55 to 84 years (474.42/100,000) = 429 Females: 74,471 x ischemic stroke incidence rate if aged 55 to 84 years (390.41/100,000) = 442 Total ischemic stroke events with current practice: 804 Part (b): To estimate the number of ischemic events if put on the intervention Males: 65,567 x ischemic stroke incidence rate if aged 55 to 84 years (474.42/100,000) x real-world medication adherence relative risk reduction estimate 0.71 = 307 Females: 74,471 x ischemic stroke incidence rate if aged 55 to 84 years (390.41/100,000) x real-world medication adherence adjusted relative risk reduction estimate 0.71 = 316 Total ischemic stroke events on intervention: 622 Net difference in stroke events = a b = 804 622 = 181
Step 3 Estimate the net quality of life benefits for each stroke prevented Number of strokes prevented for males and females are multiplied by the gender specific weighted average Quality Adjusted Life Years (QALY) lost estimates for the current practice and intervention pathways for the target group Step 4 Calculate the total intervention costs Eligible population on intervention x cost of intervention for that target group = total intervention costs. If aged 55 to 84 years without a history of stroke and with high BP: 140,038 x $725.46 = $101,591,911.
Step 5 Calculate the cost of current practice Eligible population x average weighted cost of current practice = total cost of current practice Cost of current practice is based on information in Table S5 . This annual average amount is then weighted by the proportion of people in the target group known to already by receiving treatment (Table S3) .
If aged 55 to 84 years without a history of stroke the weighted average yearly cost for that population of current practice is = ($360.51 x 22.8%) = $82.20. Total costs of current practice if aged 55 to 84 years without a history of stroke: 140,038 x $82.20 = $11,511,123
Step 6 Step 7 Calculate the cost offsets from the strokes prevented Result from Step 2 x cost-offset per first-ever or recurrent stroke (as estimated from the updated 2004 cost-of-illness models) 9 = total cost offsets If aged 55 to 84 years without a history of stroke and with high BP: 181 first-ever ischemic strokes prevented x $64,733 = $11,716,673
Step 8 Calculate the net program costs Result from Step 6 subtracted from Step 7 If aged 55 to 84 years without a history of stroke and with high BP: $90,080,787 -$11,716,673 = $78,364,114
Step 9 Calculate the net cost per QALY gained
Step 8 Costs Average costs per patient by stroke subtype and/or risk stratification category The first year intervention costs included more frequent monitoring and tests. Interventions costs beyond the first year (year 2+) were the average of year 1 and a subsequent routine year of treatment (refer Table S2 for details) Cost-offsets based on the predicted net reduction in stroke occurrences estimated as the average costs per case in the reference year Context usual care Setting Australia
Subgroup stratification
Various age bands for people without a previous stroke (primary prevention). The age group 55 to 84 years was used to assess the benefits of the intervention using an absolute risk approach since this age band conforms with the stroke specific Framingham risk stratification score 12 Cases with stroke or transient ischemic attack (secondary prevention) Absolute risk ( 15% risk of stroke over 5 years) Economic modeling Application of new MORUCOS ischemic and intracerebral hemorrhage subtypes version 2. All patients with stroke or TIA determined to not be on BP lowering medication.
3 Interventions Year 1: · Chronic disease management plan with review (n=2). · 6 other visits for titration of medication. · 3 sets of blood tests*, a 12-lead ECG and a chest Xray. Subsequent year (year 2): · 2 management plan reviews; · 2 other medical consultations (to fill scripts and review management); · 1 allied health and1 dietician consultation; and · 2 sets of blood tests*. At each visit lifestyle advice assumed to be provided. If aged 55 to 84 years and classified at high absolute risk of stroke over 5 years, prescribed a BP lowering agent, aspirin and a cholesterol-lowering agent.
Chronic disease management plan; regular review with titration of medication; and blood tests as per primary prevention schedule.* At each visit lifestyle advice assumed to be provided. *A set of blood tests included Full Blood Examination, Urea and Electrolytes, Blood glucose and Quantification of HDL cholesterol; Assumed that general practitioners addressed treatment recommendations for the various risk factors including how frequently to re-check blood pressures based on current clinical guidelines recommendations; These were different design features for the delivery of organised care that were altered and included in sensitivity testing. §Calculated using Framingham Stroke Risk Equation 12 . BP: blood pressure; TIA: transient ischemic attack. BP: blood pressure; TIA: transient ischemic attack; ICH: intracerebral haemorrhage *white population and this summary estimate used for all age groups for primary analyses; adjusted for age, ethnicity, gender and entry diastolic BP; used in a sensitivity analysis for people age 75 years and over. Note that in the economic models the relative risk reductions were adjusted to reflect realworld adherence whereby it was assumed that adherence to medication was 60% rather than 75%. ; assumptions include: 85% of population attend a general practice clinic in the reference year; 10% of general practitioners (GPs) participate; 89% of patients screened are eligible; 79% with high diastolic blood pressure get a second screen; 3.75% decline the program. Assumptions about program participation are from the Hypertension Detection and Follow-up Program 1 . Population data re access to GPs and prevalence of high blood pressure 140/90 mm Hg or absolute risk of stroke 15% over 5 years are data from relevant Australian data sources 14, 21 . conforms to age group from the Hypertension Detection and Follow-up Program trial. §this includes first-ever stroke cases in 2004 alive at 28 days and prevalent cases of stroke from 1987 to 2003 who are estimated to be still alive in 2003 and new cases of Transient Ischemic Attacks expected in 2004 based on a 0.2% prevalence rate 5, 9 . The eligible target group are those estimated to not be on blood pressure lowering medication 22 . Estimation of absolute stroke risk was undertaken using the stroke risk profile Framingham equation applicable to people aged 55 to 84 years 12 . . In addition, 78% were participating in the practice incentive program 23 . In order to be eligible for practice incentive payments, general medical practices must be accredited and meet criteria for patient throughput. Therefore, it is unlikely that universal coverage will be achieved. The additional cost per person treated with nursing incentives was $7.50. The 70% rationale was also applied to represent an expanded incentive program similar to those currently available for diabetes management. For this practice incentive program, the additional cost was estimated to be about $60 per person. This included a payment for setting up a register, a service incentive payment and outcomes payments.
